Influenza Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight

(Albany, USA) DelveInsight's, "Influenza Pipeline Insight 2024" report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in Influenza pipeline landscape. It covers the Influenza pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Influenza therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Influenza Pipeline. Dive into DelveInsight's comprehensive report today! @ Influenza Pipeline Outlook- https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Influenza Pipeline Report
• In December 2024:- ModernaTX, Inc.- A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adults ≥50 Years of Age. The purpose the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea).
• In November 2024:- DiaSorin Molecular LLC- The DiaSorin Molecular LIAISON® NES FLU A/B, RSV & COVID-19 real-time polymerase chain reaction (RT-PCR) assay is intended for use on the DiaSorin LIAISON® NES instrument for the in-vitro qualitative detection and differentiation of nucleic acid from influenza A, influenza B, RSV and SARS-CoV-2 virus from dry nasal swabs (NS) from human patients with signs and symptoms during the acute phase of respiratory tract infection in conjunction with clinical and epidemiological risk factors.
• In October 2024:- Pfizer- The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza. Influenza is a disease that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. The study vaccine is called Pandemic Influenza modRNA (pdmFlu) Vaccine.
• DelveInsight's Influenza pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Influenza treatment.
• The leading Influenza Companies such as Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others.
• Promising Influenza Therapies such as OVX836 480µg, mRNA-1010, Oseltamivir, Baloxavir, and others.

Stay ahead with the most recent pipeline outlook for Influenza. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Influenza Treatment Drugs- https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Influenza Emerging Drugs

• mRNA-1010: Moderna
mRNA-1010 is a vaccine candidate that encodes for hemagglutinin (HA) glycoproteins of the four influenza strains recommended by the World Health Organization (WHO) for the prevention of influenza, including influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages. HA is a major influenza surface glycoprotein that is considered an important target to generate broad protection against influenza and is the primary target of currently available influenza vaccines. Currently, it is in Phase III stage of clinical trial evaluation to treat patients suffering from Seasonal Influenza.

• SAB-176: SAB Biotherapeutics
SAB-176 is a quadrivalent broadly neutralizing fully-human polyclonal antibody therapeutic candidate that leverages the human biological immune response in development for the treatment of hospitalized patients with severe seasonal influenza. The novel specifically targeted therapeutic generated from the company's proprietary technology, the DiversitAb™ platform, is designed to specifically bind to Type A and Type B influenza viruses. Pre-clinical data suggests that SAB-176 offers potentially broad protection against diverse influenza strains. A highly-potent, polyclonal antibody therapy for severe seasonal influenza, could potentially treat severely ill patients and provide protective antibodies for high-risk populations, such as the elderly and immune compromised.

• INNA-051: ENA Respiratory Pty Ltd
INNA-051 is a broad-spectrum antiviral immunomodulatory nasal spray under clinical development for pre- and post-exposure prophylaxis of respiratory viral infections in populations at risk of severe complications. Based on its mechanism of action and intended route of administration, INNA-051 has the potential to address several viral respiratory pathogens across multiple patient populations with a variety of co-morbid conditions. INNA-051 antiviral efficacy is currently evaluated in a Phase 2a influenza-challenge conducted in healthy volunteers.

• CODA-VAX H1N1: Codagenix
Codagenix has utilized a design platform to construct a live-attenuated, universal flu vaccine, CodaVax™-H1N1. The vaccine enables presentation of conserved antigens of the wild-type virus, demonstrating universal potential in primate models and thus the potential to provide multi-season protection when developed into its final quadrivalent formulation. Currently, it is being evaluated in Phase I stage of clinical trial evaluation to treat Influenza virus infections.

• ALVR106: AlloVir
ALVR106 is an allogeneic, off-the-shelf, multi-virus specific VST therapy candidate designed to target diseases caused by the respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). In vitro data demonstrates that ALVR106 reactive cells have antiviral activity against each of the targeted viruses with minimal or no activity against non-virus-infected cells. This preclinical data supports the potential for antiviral benefit and safety of ALVR106 when administered to patients.

Explore groundbreaking therapies and clinical trials in the Influenza Pipeline. Access DelveInsight's detailed report now! @ New Influenza Drugs- https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Influenza Companies
Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others.

Influenza pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Influenza Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Unveil the future of Influenza Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Influenza Market Drivers and Barriers- https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Influenza Pipeline Report
• Coverage- Global
• Influenza Companies- Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others.
• Influenza Therapies- OVX836 480µg, mRNA-1010, Oseltamivir, Baloxavir, and others
• Influenza Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Influenza Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Influenza Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Influenza Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Executive Summary
3. Influenza: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Influenza - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. mRNA-1010: Moderna
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. INNA-051: ENA Respiratory Pty Ltd
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CODA-VAX H1N1: Codagenix
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Influenza Key Companies
21. Influenza Key Products
22. Influenza- Unmet Needs
23. Influenza- Market Drivers and Barriers
24. Influenza- Future Perspectives and Conclusion
25. Influenza Analyst Views
26. Influenza Key Companies
27. Appendix

Trending Reports:
• Artificial Lung Devices Market: https://www.delveinsight.com/report-store/artificial-lung-devices-pipeline-insight-and-competitive-landscape
• Cerebral Vein Thrombosis Market: https://www.delveinsight.com/report-store/cerebral-vein-thrombosis-market
• Dlbcl Market: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Generalized Anxiety Disorder Gad Market: https://www.delveinsight.com/report-store/generalized-anxiety-disorder-gad-market
• Healthcare Competitive Intelligence: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market-forecast
• Neurovascular Thrombectomy Devices Market: https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
• Optic Neuritis Market: https://www.delveinsight.com/report-store/optic-neuritis-market
• Pd-1 & Pdl1 Market: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Pemphigus Vulgaris Market: https://www.delveinsight.com/report-store/pemphigus-vulgaris-market
• Peripheral Neuropathic Pain Market: https://www.delveinsight.com/report-store/peripheral-neuropathic-pain-market
• Vernal Keratoconjunctivitis Market: https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infection-absssi-market-insights-epidemiology-and-market-forecast
• Achromatopsia Market: https://www.delveinsight.com/report-store/achromatopsia-market
• Acid Sphingomyelinase Deficiency Market: https://www.delveinsight.com/report-store/acid-sphingomyelinase-deficiency-asmd-market
• Acne Vulgaris Market: https://www.delveinsight.com/report-store/acne-vulgaris-av-market
• Acquired Immunodeficiency Syndrome Market: https://www.delveinsight.com/report-store/acquired-immunodeficiency-syndrome-aids-pipeline-insight
• Acute On Liver Failure Market: https://www.delveinsight.com/report-store/acute-liver-failure-market
• Acute Pharyngitis Market: https://www.delveinsight.com/report-store/acute-pharyngitis-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Adult Onset Still Disease Market: https://www.delveinsight.com/blog/adult-onset-stills-disease-treatment-market
• Advanced Hepatocellular Carcinoma With Cpb Liver Cirrhosis Market: https://www.delveinsight.com/report-store/advanced-hepatocellular-carcinoma-with-cpb-liver-cirrhosis-market-insight
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Alkaptonuria Market: https://www.delveinsight.com/report-store/alkaptonuria-market
• Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.